PGNY Progyny, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Fertility benefits solution providing proprietary Smart Cycle treatment bundles with care management and pharmacy benefits add-on
• • New emphasis on expanded women's health and family building services including pregnancy/postpartum and menopause, strategic investments but not material revenue yet
• • Strategic client diversification: expanded to 555 clients across 40+ industries from only 2 at launch, focusing on larger clients with >2,500 covered lives
• • Membership grew to 6.7 million covered lives (3.3% increase YoY), revenue increased 10% to $1.29B with fertility benefits up 14% and pharmacy up 5%
• • Noteworthy cost structure improvement: gross margin expanded 190 basis points to 23.6%, driven by efficiencies in care management services delivery

Risk Factors

• • No specific, timely regulatory or legal risk identified
• • Economic impacts from potential changes in healthcare funding affect Progyny's fertility benefits offerings, no quantification provided
• • Operational risk from maintaining employee engagement during fast growth with 856 employees, critical to execution and retention
• • Market disruption risk from competitors advancing fertility and family-building technologies impacting demand for Progyny services
• • No financial or structural risk detail (e.g., leverage or key person) disclosed in this section

Management Discussion & Analysis

• • No revenue or profitability data disclosed in this section, focus on risks to network and operations
• • Key segment: Center of Excellence fertility network, risk of losing providers or higher costs impacting margins
• • Specialty pharmacy segment risk: supply disruptions or pricing changes could increase costs and reduce profitability
• • No cash flow, buybacks, dividends, or capex information provided in this text
• • Forward risks: regulatory changes, contract termination threats, competitive pressures, and provider consolidation potentially harming growth and margins

What are the latest PGNY SEC filings in 2026?

Progyny, Inc. (PGNY) has filed a 10-K annual report on February 27, 2026, a 10-Q quarterly report on May 8, 2026, an 8-K current report on May 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PGNY file its most recent 10-K annual report?

Progyny, Inc. (PGNY) filed its most recent 10-K annual report on February 27, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PGNY 10-Q quarterly reports?

Progyny, Inc. (PGNY)'s most recent 10-Q quarterly report was filed on May 8, 2026. SignalX displays every PGNY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PGNY filed recently?

Progyny, Inc. (PGNY)'s most recent 8-K was filed on May 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PGNY insider trading activity (Form 4)?

SignalX aggregates every PGNY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PGNY file with the SEC?

Progyny, Inc. (PGNY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PGNY filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Progyny, Inc. (PGNY).

What is PGNY's SEC CIK number?

Progyny, Inc. (PGNY)'s SEC CIK (Central Index Key) number is 1551306. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1551306 to look up all PGNY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PGNY return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Progyny, Inc. (PGNY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.